BioCentury
ARTICLE | Clinical News

SQ109: Phase IIa start

October 25, 2010 7:00 AM UTC

By year end, Sequella will begin an open-label, African Phase IIa trial in 90 patients to evaluate 75, 150 and 300 mg oral SQ109 once daily, 150 or 300 mg SQ109 plus 150 mg rifampicin once daily, or 1...